VALIRX PLC

Share Issue/Capital Change • Oct 2, 2020

National Storage Mechanism | Additional information

RNS Number : 0054B

ValiRx PLC

02 October 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Exercise of Warrant

London, UK 2 October 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces it has received notification for the exercise of warrants over 40,000 ordinary shares in the Company at an exercise price of 12.5 pence per share providing the Company with proceeds of £5,000 ("Warrant Exercise").

Application will be made to the London Stock Exchange to admit the 40,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 8 October 2020.  The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 64,028,325 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

ValiRx plc	Tel: +44 (0) 20 7073 2628 www.valirx.com
Suzanne Dilly	Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: +44 (0) 20 8148 3040 valirx@optimumcomms.com

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance. 

Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEEALEAELSEFFA